Bessemer Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bessemer Group’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,064	Closed	-$99K	–	2113
2022 Q4	$99K	Hold	3,064	–	–	﹤0.01%	1042
2022 Q3	$128K	Hold	3,064	–	–	﹤0.01%	981
2022 Q2	$129K	Hold	3,064	–	–	﹤0.01%	975
2022 Q1	$208K	Hold	3,064	–	–	﹤0.01%	817
2021 Q4	$372K	Hold	3,064	–	–	﹤0.01%	708
2021 Q3	$431K	Buy	+3,064	New	+$607K	﹤0.01%	603

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's EVLO Position: Q1 2023 in Review

Bessemer Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 3,064 shares — an estimated $99K sold.

Bessemer Group first reported a position in EVLO in Q3 2021 and held it in 6 quarters. The position peaked at $431K in Q3 2021. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

Bessemer Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Bessemer Group sold 3,064 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $99K.
Bessemer Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Bessemer Group's Evelo Biosciences, Inc. Common Stock position peaked at $431K in Q3 2021.
39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Bessemer Group's 13F filing for Q1 2023, filed 10 May 2023.